Table 1 Correlated drugs
From: Understanding drugs in breast cancer through drug sensitivity screening
Drug 1 | Drug 2 | p-value | Pearson correlation coefficient |
|---|---|---|---|
MI-219 | Nutlin-3 | 1.77E−28 | 0.98 |
Panobinostat (Faridak®) | Vorinostat (Zolinza®) | 2.14E−24 | 0.96 |
Panobinostat (Faridak®) | Quisinostat | 1.66E−19 | 0.93 |
Belinostat | Vorinostat (Zolinza®) | 2.05E−18 | 0.92 |
Belinostat | Panobinostat (Faridak®) | 1.70E−16 | 0.91 |
Erlotinib (Tarceva®) | Gefitinib (Iressa®) | 3.49E−14 | 0.88 |
Quisinostat | Vorinostat (Zolinza®) | 1.05E−13 | 0.87 |
Belinostat | Quisinostat | 8.08E−13 | 0.85 |
Paclitaxel (Taxol®, OnxalTM) | Docetaxel (Taxotere®) | 4.61E−08 | 0.73 |
Azacitidine (Vidaza®) | Doxorubicin (Adriamycin®) | 3.77E−07 | 0.7 |
JNJ-493 | JNJ-707 | 1.39E−05 | 0.62 |
Decitabine (Dacogen®) | 5-Fluorouracil | 7.77E−05 | 0.58 |
Decitabine (Dacogen®) | Serdemetan | 1.17E−04 | 0.56 |
Vandetanib (Zactima®) | Gefitinib (Iressa®) | 1.52E−04 | 0.56 |
Serdemetan | Tipifarnib (Zarnestra®) | 5.15E−04 | 0.52 |
Decitabine (Dacogen®) | Lapatinib | 5.29E−04 | 0.52 |
Veliparib | Serdemetan | 5.47E−04 | 0.51 |
JNJ-493 | Sunitinib (Sutent®) | 1.37E−03 | 0.48 |
Veliparib | Decitabine (Dacogen®) | 1.63E−03 | 0.48 |
Vandetanib (Zactima®) | Erlotinib (Tarceva®) | 1.78E−03 | 0.47 |
Bortezomib (Velcade®) | Vandetanib (Zactima®) | 1.94E−03 | 0.47 |
ARQ197 | Docetaxel (Taxotere®) | 1.95E−03 | 0.47 |
Cisplatin | Sunitinib (Sutent®) | 2.00E−03 | 0.47 |
JNJ-707 | Brivanib | 2.16E−03 | 0.46 |
Mitoxantrone (Novantrone®) | JNJ-707 | 2.98E−03 | 0.45 |
JNJ-707 | Nutlin-3 | 2.87E−03 | −0.45 |
Cisplatin | Azacitidine (Vidaza®) | 2.16E−04 | −0.55 |
JNJ-208 | Bortezomib (Velcade®) | 1.96E−06 | −0.66 |
Cisplatin | Doxorubicin (Adriamycin®) | 5.22E−08 | −0.73 |